PROCEPT BioRobotics Corp NASDAQ:PRCT 的执行副总裁兼首席财务官Kevin Waters于2026年3月17日出售了706股普通股。这些股票的出售价格为$28.1532,交易总价值为$19,876。

Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the ...

PROCEPT BioRobotics trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth. Learn why PRCT stock is a buy.

PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported ...

根据向美国证券交易委员会提交的4号表格文件,PROCEPT BioRobotics Corp(纳斯达克股票代码:PRCT)执行副总裁兼首席法务官、公司秘书Alaleh ...

The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on December 18, 2025. The analyst firm set a price target for $47.00 expecting PRCT to rise to within 12 ...

Ratings for PROCEPT BioRobotics (NASDAQ:PRCT) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the best medical device stocks to buy according to analysts. On August 8, Leerink Partners analyst Mike Kratky reiterated a Buy rating on ...

Full-year 2025 revenue guidance was updated to approximately $323 million, reflecting 44% growth compared to 2024. This includes US system revenue of $95 million, driven by greenfield sales and some ...

Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasiaSAN JOSE, Calif., March 23, ...

PROCEPT BioRobotics' Aquablation therapy has been upgraded to a strong recommendation in the updated European Association of Urology Guidelines as a preferred surgical treatment for benign prostatic ...

The average one-year price target for PROCEPT BioRobotics (NasdaqGM:PRCT) has been revised to $33.58 / share. This is a decrease of 37.60% from the prior estimate of $53.80 dated February 21, 2026.